

HETEROCYCLES, Vol. 69, 2006, pp. 469 - 474. © The Japan Institute of Heterocyclic Chemistry
Received, 22nd June, 2006, Accepted, 17th August, 2006, Published online, 18th August, 2006. COM-06-S(O)21

LYCOVATINE A, a C₁₆N-TYPE QUATERNARY ALKALOID FROM *LYCOPODIUM CLAVATUM* VAR. *ROBUSTUM*


Takaaki Kubota,^a Tomoe Sunaura,^a Hiroshi Morita,^b Yuzuru Mikami,^c Tomohiro Hoshino,^d Yutaro Obara,^d Norimichi Nakahata,^d and Jun'ichi Kobayashi^{a,*}

a: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan; b: Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan; c: Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba 260-0856, Japan; d: Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan. E-mail: jkobay@pharm.hokudai.ac.jp.

Abstract - A new C₁₆N-type quaternary alkaloid, lycovatine A (**1**), has been isolated from the club moss *Lycopodium clavatum* var. *robustum*, and the structure including the relative stereochemistry was elucidated on the basis of spectroscopic data.

INTRODUCTION

Club moss (Lycopodiaceae) are known to be a rich source of *Lycopodium* alkaloids possessing unique heterocyclic ring systems such as C₁₆N, C₁₆N₂, and C₂₇N₃, which have attracted great interest from biogenetic, synthetic, and biological points of view.¹ In our continuing efforts to find new *Lycopodium* alkaloids,² a new *N*-methylated C₁₆N-type quaternary alkaloid, lycovatine A (**1**), was isolated from the club moss *Lycopodium clavatum* var. *robustum*. In this paper, we describe the isolation and structure elucidation of **1**.



lycovatine A (**1**)

RESULTS AND DISCUSSION

The club moss *L. clavatum* var. *robustum* collected at Nayoro in Hokkaido were extracted with MeOH, and the MeOH extract was partitioned between EtOAc and 3% tartaric acid. Water-soluble materials, which were adjusted at pH 10 with saturated Na₂CO₃, were partitioned with CHCl₃. CHCl₃-soluble materials were purified by an amino silica gel column (hexane/EtOAc and then CHCl₃/MeOH) followed by C₁₈ HPLC (CH₃CN/0.1% CF₃CO₂H, 15:85) to afford lycovatine A (**1**, 0.0002% yield) together with a known alkaloid, lycodoline³.

Table 1. ¹H and ¹³C NMR Data of Lycovatine A (**1**) in CD₃OD

Position	δ _H		δ _C	
1a	3.79	(1H, m)	59.5	t
1b	3.47	(1H, m)		
2a	3.12	(1H, m)	28.2	t
2b	2.63	(1H, m)		
3	6.07	(1H, d, 6.7)	125.9	d
4			149.1	s
5	4.65	(1H, d, 7.4)	75.6	d
6a	2.28	(1H, m)	38.3	t
6b	1.45	(1H, d, 14.7)		
7	2.20	(1H, m)	48.2	d
8a	1.65	(1H, m)	39.9	t
8b	1.53	(1H, m)		
9a	3.69	(1H, m)	59.4	t
9b	3.47	(1H, m)		
10a	2.17	(1H, m)	21.2	t
10b	1.75	(1H, m)		
11a	2.18	(1H, m)	28.7	t
11b	1.53	(1H, m)		
12			57.3	s
13			100.7	s
14a	2.06	(1H, brd)	36.3	t
14b	1.98	(1H, t, 11.4)		
15	1.98	(1H, m)	30.4	d
16	1.02	(3H, d, 5.6)	32.3	q
17	3.00	(3H, s)	51.3	q

Lycovatine A (**1**) was revealed to have the molecular formula, $C_{17}H_{28}N_1O_2$, by HRESIMS data [m/z 278.2120, $(M)^+$, ± 0.0 mmu]. IR absorptions implied the presence of hydroxy group (3400 cm^{-1}). The ^1H and ^{13}C NMR (Table 1) spectra of **1** showed signals due to one sp^2 quaternary carbon, two sp^3 quaternary carbons, one sp^2 methine, three sp^3 methines, eight sp^3 methylenes, and two methyls. Among them, one methyl (δ_{C} 51.3) and two methylenes (δ_{C} 59.4, and 59.5) were ascribed to those bearing a nitrogen atom, while one sp^3 quaternary carbon (δ_{C} 100.7) was ascribed to that bearing an oxygen and a nitrogen atoms.

The ^1H - ^1H COSY and HOHAHA spectra revealed connectivities of C-1 to C-3, C-5 to C-6, C-7 to C-8, C-14 to C-16, C-8 to C-15, and C-9 to C-11. These partial units were connected to each other on the basis of HMBC correlations of H-3 to C-5 and C-12, H-5 to C-7, H-6 to C-4 and C-12, and H-1, H-9, H-11, and H-14 to C-13. The presence of an *N*-methyl group (C-17) was revealed by HMBC correlations of H-17 to C-1, C-9 and C-13. Thus, the gross structure of lycovatine A was elucidated to be **1** (Figure 1).




Figure 1. Selected 2D NMR correlations for lycovatine A (**1**)

The relative stereochemistry of **1** was deduced from cross-peaks observed in the NOESY spectrum as shown in computer-generated 3D drawing (Figure 2). These NOESY correlations indicated the relative stereochemistry of C-5 and C-15 as well as chair forms of a cyclohexane (C-7 to C-8 and C-12 to C-15) and a piperidine (N-1 and C-9 to C-13) rings in the trans fused decahydroquinoline moiety.

The absolute configuration of lycovatine A (**1**) was elucidated by applying the modified Mosher's method.⁴ To elucidate the absolute configuration at C-5, **1** was converted into its (*S*)- and (*R*)-2-methoxy-2-trifluoromethylphenylacetic acid (MTPA) ester of the hydroxy group at C-5. The $\Delta\delta$ [$\delta(S\text{-MTPA ester}) - \delta(R\text{-MTPA ester})$] values obtained from the ^1H NMR spectra of the MTPA esters suggested that the absolute configuration at C-5 was *R*.





Figure 2. Selected NOESY correlations and relative stereochemistry for lycovatine A (**1**)

Lycovatine A (**1**) is a rare *N*-methyl fawcettidane-type⁵ quaternary alkaloid from *Lycopodium clavatum* var. *robustum*, although some quaternary alkaloids such as senepodines B, D, and H^{6,7} from club moss (Lycopodiaceae) have been reported. A plausible biogenetic path of lycovatine A (**1**) was proposed as shown in Scheme 1. Biogenetically, lycovatine A (**1**) might be derived from lycodoline³ through a fawcettidane-type intermediate **A**. Effects of lycovatine A (**1**) on neurotrophic factor biosynthesis in 1321N1 human astrocytoma cells were examined by a semiquantitative RT-PCR method^{8,9} to find that the mRNA expressions for NGF were enhanced by **1**. Lycovatine A (**1**) did not show cytotoxicity against murine leukemia L1210 cells and human epidermoid carcinoma KB cells ($IC_{50} > 10 \mu\text{g/mL}$). Lycovatine A (**1**) exhibited antimicrobial activity against *Cryptococcus neoformans* (MIC, $0.52 \mu\text{g/mL}$) and *Aspergillus niger* (MIC, $2.05 \mu\text{g/mL}$).



Scheme 1. Plausible biogenetic path of lycovatine A (**1**)

EXPERIMENTAL

General Experimental Procedures.

IR spectra were recorded on a JASCO FT/IR-230 and a Shimadzu UV-1600PC spectropolarimeter. ^1H and ^{13}C NMR spectra were recorded on a Bruker AMX-600 spectrometer using 2.5 mm micro cells (Shigemi Co., Ltd). The 3.31 and 49.5 ppm resonances of residual CD_3OD were used as internal references for ^1H and ^{13}C NMR spectra, respectively. ESI mass spectra were obtained on a JEOL JMS-700TZ spectrometer.

Plant Material.

The club moss *Lycopodium clavatum* var. *robustum* was collected at Nayoro in Hokkaido in 2001. The botanical identification was made by Mr N. Yoshida, Health Sciences University of Hokkaido. A voucher specimen has been deposited in the herbarium of Hokkaido University.

Extraction and Isolation.

The club moss *Lycopodium clavatum* var. *robustum* (0.9 kg) was crushed and extracted with MeOH. A portion of the MeOH extract was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with saturated Na_2CO_3 (aq.) to pH 10 and extracted with CHCl_3 . The CHCl_3 soluble materials were subjected to an amino silica gel column (hexane/EtOAc to $\text{CHCl}_3/\text{MeOH}$) followed by C18 HPLC (15% $\text{CH}_3\text{CN}/0.1\%$ $\text{CF}_3\text{CO}_2\text{H}$) to afford lycovatine A (**1**, 0.0002% yield) and lycodoline³) (0.0006% yield).

Lycovatine A (1): colorless amorphous solid; $[\alpha]_{\text{D}}^{23} -8^\circ$ (*c* 0.1, MeOH); IR (KBr) ν_{max} 3420 and 2920 cm^{-1} ; ^1H and ^{13}C NMR data (Table 1); ESIMS m/z 278 (M^+); HRESIMS m/z 278.212 (M ; calcd for $\text{C}_{17}\text{H}_{28}\text{N}_1\text{O}_2$, 278.212).

(R)- and (S)-MTPA Esters of Lycovatine A (1). To a pyridine solution (50 μL) of **1** (0.1 mg) was added 4-dimethylaminopyridine (50 μg), triethylamine (2 μL), and (*S*)-(+)-MTPACl (1 μL), and stirring was continued at 40 $^\circ\text{C}$ for 23 h. After addition of *N,N*-dimethyl-1,3-propanediamine (1 μL) and H_2O (100 μL), the mixture was extracted with EtOAc (100 μL x 3), and the extract was concentrated in *vacuo* to afford the (*R*)-MTPA ester of **1** (0.1 mg). The (*S*)-MTPA ester of **1** was prepared according to the same procedure as described above.

(S)-MTPA ester of 1: ^1H NMR (CDCl_3) δ 5.95 (1H, H-3), 5.72 (1H, H-5), 3.55 (3H, H_3 -17), 3.17 (1H, H-9a), 3.07 (1H, H-9b), 2.91 (2H, H_2 -1), 2.64 (1H, H-2a), 2.38 (1H, H-7), 2.34 (1H, H-2b), 2.33 (1H, H-11a), 2.29 (1H, H-10a), 2.29 (1H, H-14a), 2.22 (1H, H-14b), 2.15 (1H, H-6a), 1.93 (1H, H-15), 1.92 (1H, H-10b), 1.72 (1H, H-6b), 1.47 (1H, H-11b), 1.47 (1H, H-8a), 1.27 (1H, H-8b), 0.86 (3H, H_3 -16); ESIMS m/z 494 ($\text{M}+\text{H}^+$).

(R)-MTPA ester of 1: ^1H NMR (CDCl_3) δ 6.08 (1H, H-3), 5.79 (1H, H-5), 3.54 (3H, H₃-17), 3.18 (1H, H-9a), 3.17 (1H, H-1a), 3.04 (1H, H-1b), 2.99 (1H, H-9b), 2.74 (1H, H-2a), 2.40 (1H, H-2b), 2.23 (1H, H-7), 2.44 (1H, H-14a), 2.40 (1H, H-11a), 2.25 (1H, H-6a), 2.24 (1H, H-14b), 2.07 (1H, H-10a), 1.88 (1H, H-15), 1.80 (1H, H-10b), 1.57 (1H, H-6b), 1.56 (1H, H-11a), 1.47 (1H, H-8a), 1.01 (1H, H-8a), 0.79 (3H, H₃-16); ESIMS m/z 494 ($\text{M}+\text{H}$)⁺.

ACKNOWLEDGEMENTS

The authors thank Ms. S. Oka and Ms. M. Kiuchi, Center for Instrumental Analysis, Hokkaido University, for measurements of ESIMS, and Mr. N. Yoshida, Health Sciences University of Hokkaido, for botanical identifications of the plant. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

REFERENCES

1. For reviews of *Lycopodium* alkaloids, see: (a) J. Kobayashi and H. Morita, *The Alkaloids*; ed. by G. A. Cordell; Academic: New York, 2005; Vol. 61, p. 1. (b) W. A. Ayer and L. S. Trifonov, *The Alkaloids*; ed. by G. A. Cordell and A. Brossi; Academic: New York, 1994; Vol. 45, p. 233. (c) W. A. Ayer, *Nat. Prod. Rep.*, 1991, **8**, 455. (d) D. B. MacLean, *The Alkaloids*; ed. by A. Brossi; Academic: New York, 1985; Vol. 26, p. 241. (e) D. B. MacLean, *The Alkaloids*; ed. by R. H. F. Manske; Academic: New York, 1973; Vol. 14, p. 348. (f) D. B. MacLean, *The Alkaloids*; ed. by R. H. F. Manske; Academic: New York, 1968; Vol. 10, p. 305.
2. K. Ishiuchi, T. Kubota, H. Morita, and J. Kobayashi, *Tetrahedron Lett.*, 2006, **47**, 3287.
3. H. Ishii, B. Yasui, T. Harayama, and Y. Inubushi, *Tetrahedron Lett.*, 1966, 6215.
4. I. Ohtani, T. Kusumi, Y. Kashman, and H. Kakisawa, *J. Am. Chem. Soc.*, 1991, **113**, 4092.
5. W. A. Ayer and G. G. Iverach, *Can. J. Chem.*, 1964, **42**, 2514.
6. Y. Hirasawa, H. Morita, and J. Kobayashi, *Tetrahedron*, 2003, **59**, 3567.
7. H. Morita, Y. Hirasawa, T. Shinzato, and J. Kobayashi, *Tetrahedron*, 2004, **60**, 7015.
8. Y. Obara, H. Kobayashi, T. Ohta, Y. Ohizumi, and N. Nakahata, *Mol. Pharmacol.*, 2001, **59**, 1287.
9. H. Morita, K. Ishiuchi, A. Haganuma, T. Hoshino, Y. Obara, N. Nakahata, and J. Kobayashi, *Tetrahedron*, 2005, **61**, 1955.